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Background: Implementation of the 2010 Affordable Care Act (ACA) calls for a collaborative effort to transform the U.S. health care system toward
patient-centered and value-based care. To identify how specialty care can be improved, we mapped current U.S. health care utilization in patients with
inflammatory bowel diseases (IBD) using a national insurance claims database.
Methods: We performed a cross-sectional study analyzing U.S. health care utilization in 964,633 patients with IBD between 2010 and 2012 using
insurance claims data, including pharmacy and medical claims. Frequency of IBD-related care utilization (medication, tests, and treatments) and their
charges were evaluated. Subsequently, outcomes were put into the framework of current U.S. guidelines to identify areas of improvement.
Results: A disproportionate usage of aminosalicylates in Crohn’s disease (42%), frequent corticosteroid use (46%, with 9% long-term users), and low
rates of corticosteroid-sparing drugs (thiopurines 15%; methotrexate 2.7%) were observed. Markers for inflammatory activity, such as C-reactive protein
or fecal calprotectin were not commonly used (8.8% and 0.13%, respectively). Although infrequently used (11%), anti-TNF antibody therapy represents
a major part of observed IBD charges.
Conclusions: This analysis shows 2010–2012 utilization and medication patterns of IBD health care in the United States and suggests that improve-
ment can be obtained through enhanced guidelines adherence.
(Inflamm Bowel Dis 2014;20:1747–1753)
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T he current U.S. health care system is suffering from a varietyof clinical and economic inefficiencies.1–3 Although the focus
of debates on these challenges may vary, such as excessive
administration, nonadherence to guidelines, overutilization of
resources, uncoordinated care, and broad-based preventive fail-
ures, there is an emerging consensus that the U.S. health care
system as currently implemented, with a persistent disconnection
between high spending levels and discernible improvements in
patient outcomes, is not sustainable.
Inflammatory bowel diseases (IBD) are prototypic chronic
diseases, affecting around 1.4 million adults and children in the
United States. The estimated annual disease-attributable direct
costs are largely driven by hospital costs and medication,
especially biological therapy.4,5 Like most chronic diseases, IBD
care is beset with wide practice variations,6 provider expertise
differentials (primary and specialty), and a limited evidence base
for basic, let alone integrated, standards of care and quality of
care.7 Fragmentation and duplication of services, suboptimal
follow-up, and a lack of transparency in adherence to guidelines,
particularly regarding overuse and misuse of drugs, could contrib-
ute as well to the high spending in IBD care.
We conducted a 2010–2012 insurance claims analysis encom-
passing 964,633 patients with IBD. The primary study objective was
to assess U.S. health care utilization in patients with IBD on a national
level to establish a detailed understanding of current practices in IBD
management. The secondary objective was to analyze charges
encountered for different aspects of IBD management and assess
their relative contribution to total IBD-related health care costs.
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METHODS
Claims-derived Care Analysis
We conducted a retrospective analysis of U.S. IBD
pharmacy and medical claims data, between 2010 and 2012,
from Source Healthcare Analytics LLC (SHA). The data represent
a significant proportion of all U.S. medical and pharmacy claims
enabling quantitative/qualitative assessments of IBD-related prac-
tices and costs. Only fully adjudicated claims by both payers and
providers were included. Patients with IBD were identified as
having $1 medical claim with one of the ICD-9 codes for
Crohn’s disease (CD) (555.x) or ulcerative colitis (UC) (556.x)
between April 2010 and March 2012. Patients with diagnosis
codes for both UC and CD were excluded from the disease spe-
cific analyses. We analyzed medical claims for patient identifiers,
demographics, procedure details, charge, date, and physician
information. Pharmacy claims for IBD-specific drugs (Table, Sup-
plemental Digital Content 1, http://links.lww.com/IBD/A522)
were analyzed for patient identifiers, demographics, prescription
details, charge, date, insurance, and physician information. A
summary of the claims data capture process is shown in Figure,
Supplemental Digital Content 2, http://links.lww.com/IBD/A523.
Heatmaps were generated based on UC and CD pharmacy claim
counts in different U.S. regions, by physician 3-digit zip codes,
divided by the assumed population sizes of these regions.
Medications were categorized into 6 groups of ascending
potency: (1) aminosalicylates, (2) antibiotics, (3) budesonide, (4)
systemic corticosteroids, (5) immunomodulators, and (6) biologic
therapy (Table, Supplemental Digital Content 1, http://links.lww.
com/IBD/A522). We determined the number of unique patients
using these drugs between 2010 and 2012. Biologics, in particular
intravenous infliximab and intravenous natalizumab, are com-
monly charged as medical claims, which were therefore included
as well. For each drug group, the percentage prescribed by gastro-
enterologists was calculated. To determine concomitant medica-
tion use, we analyzed prescription rates in 3-month timeframes. In
addition, we calculated the percentage of patients using cortico-
steroids for more than 105 consecutive days. To quantify the
volume of patients discontinuing immunomodulators or biologics,
we defined stopping as not receiving a refill within 30 days after
the end date of the last prescription.
For the analysis of IBD-related procedures and tests, total
claim counts, unique patient counts, and charges were extracted
from the medical claims data set. IBD-related procedures
were defined based on a predefined set of Current Procedural
Terminology (CPT) and Healthcare Common Procedure Coding
System Codes summarized in Table, Supplemental Digital Content
3, http://links.lww.com/IBD/A524. The included CPT codes cover
gastrointestinal surgical procedures, anesthesia, and medical proce-
dures; laboratory, pathology, and radiological procedures; and co-
des for evaluation and management. In addition, we included CPT
category 2 codes for IBD-specific quality measures8 and CPT cat-
egory 3 codes for gastrointestinal procedures. The included Health
care Common Procedure Coding System level II codes were
A-codes for stoma care, B-codes for (par)enteral therapies, and
J-, C-, and S-codes for IBD-specific drugs (Table, Supplemental
Digital Content 3, http://links.lww.com/IBD/A524).
Charge Analysis
Since neither costs nor reimbursement rates are publicly
known, costs in this study refer to claims-related charges and
were used to assess the relative contribution of different
medications and procedures to total IBD-related charges. Patient
identifiers, and thus information regarding diagnoses, were only
available for a subset of all pharmacy claims; therefore,
deidentified claims for IBD-related medications prescribed by
gastroenterologists were also collected for charge estimations.
For each claim, physician and insurance information, prescription
details, charges, and claim month were obtained. We corrected
for the subset of patients with IBD that is not managed by
gastroenterologists, using the proportion of IBD medication
prescribed by nongastroenterologists in the IBD patient-
identified pharmacy claims data set. To assess the charges of
IBD-related procedures and tests, the medical claims data set was
used. For claims without a charge, the average of charges per
procedure with a known charge was used.
Guidelines-derived Care Analysis
We critically appraised and summarized all available U.S.
guidelines, medical position statements, and technical reviews
from the American College of Gastroenterology (ACG) and the
American Gastroenterological Association (AGA). Where differ-
ent sets of guidelines disagreed on specific management deci-
sions, the most conservative measure was used in our analysis.
The guidelines-derived data sets were structured in a way that
would enable comparison with the claims-derived data analysis.
Statistical Analysis
Our descriptive statistics consist of patient and physician
demographics, medication and medical resources utilization, and
charges. All outcomes were analyzed for all patients with
a diagnosis of IBD, and per diagnosis specifically (UC versus
CD). All statistical analyses were performed on the SHA-retrieved
data sets using SAS software (version 9.2; SAS, Cary, NC).
RESULTS
Claims-derived Care Analysis
Between 2010 and 2012, a total of 964,633 patients with
IBD was identified: 501,718 patients with CD (52%) and 529,788
patients with UC (55%); 7% had a diagnosis code for both UC
and CD. The mean age of the study population was 50.8 (SD
18.1) years (CD, 48.3 [SD 18.3] yr; UC, 52.6 [SD 17.7] yr), and
44% was male (43% CD and 45% UC). In the pharmacy claims
data set, a total of 413,334 patients with IBD was identified who
had at least 1 pharmacy claim for IBD-related medication; 39% of
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these claims were processed by commercial insurers, 30% by
a pharmacy benefit manager, 14% by Medicare, 6% by Medicaid,
8% by an employer group, and 3% paid cash (Table, Supple-
mental Digital Content 4, http://links.lww.com/IBD/A525). Geo-
graphical heatmaps that show the relative amount of claims per
3-digit zip code area are provided in Figure, Supplemental Digital
Content 5, http://links.lww.com/IBD/A526 for CD and UC.
Pharmacy Claims Analysis
Table 1 summarizes observed use of IBD medication, sub-
divided for CD and UC. In our study population, 62% of patients
with UC and 42% of patients with CD used aminosalicylates. In
total, 32% of all aminosalicylate claims were prescribed for pa-
tients with CD. Antibiotics were used by 21% of patients with UC
and 25% with CD, and corticosteroids were used in 46% of pa-
tients with IBD (CD 47%, UC 44%). Long-term use of cortico-
steroids was observed in 8.8% of patients (19% of all
corticosteroid users) within the study period. Concomitant use
of corticosteroid-sparing medication, i.e., immunosuppressives,
was low (15% used thiopurines concomitant with corticosteroids,
2.7% used methotrexate) (Table 2). In total, 18% of patients used
thiopurines (CD 21%, UC 12%), 2.6% methotrexate, and 0.2%
cyclosporine. Of patients with UC receiving thiopurines, 59%
continued the use of aminosalicylates; for methotrexate, this
was 31%. We observed that 54% of patients who used immuno-
modulators stopped, of whom 73% restarted again. The number of
patients with CD who used infliximab, adalimumab, certolizumab
pegol, or natalizumab was 6.0%, 9.2%, 2.5%, and 0.1%, respec-
tively; for patients with UC, these rates were 2.1%, 1.3%, 0.2%,
and 0%, respectively. Of patients taking biologics, 48% stopped,
of whom 74% restarted. The majority of biologics (69%), immu-
nomodulators (63%), aminosalicylates (64%), and budesonide
(69%) were prescribed by gastroenterologists. Nongastrointestinal
specialists prescribed most of the corticosteroids (70%) and anti-
biotics (71%).
Medical Claims Analysis
A total of 12,374,156 medical claims were identified
between 2010 and 2012, covering 6405 different claim codes.
Of these codes 1750 (27%) were IBD-related, corresponding with
9,818,429 claims (79% of the total claims). The most common
claims were 15-minute office visit (684,790 claims), 25-minute
office visit (641,367 claims), complete blood count (514,459
claims), venipuncture (513,527 claims), and colonoscopy with
biopsies (467,980 claims).
The average rate of annual outpatient clinic visits was
94%, ER visits 11%, hospitalizations 6.5%, and surgeries 2.8%
(Table 3). The rate of outpatient clinic visits was higher for CD
(97%) compared with UC (74%). Annual colonoscopy rates were
25% for CD and 34% for UC. The annual rate of imaging (ultra-
sound, magnetic resonance imaging, or computed tomography
abdomen/pelvis) was 18%, of complete blood count 32%,
and of liver enzyme tests 20%. Annual rates of inflammatory
activity assessment using biomarkers were as follows: C-reactive
protein 8.8%, ESR 9.7%, fecal calprotectin 0.13%, fecal lacto-
ferrin 0.13%, and fecal leukocytes 0.32%. During the study
period, 1.0% of patients underwent a dual-energy x-ray absorp-
tiometry scan. Determination of the rate of thiopurine methyl-
transferase testing and thiopurine metabolites did not result in
reliable results, because multiple CPT codes are used for these
TABLE 1. Percentage of Patients with IBD/CD/UC
Using IBD Drugs Between 2010 and 2012
IBD, % CD,% UC, %
Aminosalicylates 53.1 42.1 62.3
Antibiotics 23.5 25.2 20.7
Budesonide 8.0 12.0 3.7
Systemic corticosteroids 46.3 47.0 44.4
Long-term corticosteroids 8.8 8.3 8.4
Thiopurines 17.5 21.3 12.3
Methotrexate 2.6 3.4 1.6
Cyclosporine 0.2 0.2 0.2
Biologics 11.0 16.8 3.5
TABLE 2. Concomitant Drug Use
Concomitant Drug Use
Aminosalicylates Systemic Corticosteroids Thiopurines Methotrexate Biologicsa
IBD Total CD UC IBD Total CD UC IBD Total CD UC IBD Total CD UC IBD Total CD UC
Aminosalicylates, % · · · 34 25 42 42 30 59 25 20 31 13 11 24
Systemic corticosteroids, % 15 15 15 · · · 19 16 22 29 25 35 13 11 16
Thiopurine, % 14 17 12 15 15 13 · · · 3 4 2 10 10 9
Methotrexate, % 1 1 1 3 3 2 0 0 0 · · · 3 3 5
Biologics, %a 2 3 1 4 6 1 4 5 1 10 12 5 · · ·
Percentages of patients on drug A (columns) concomitantly using drug B (rows).
aBecause this analysis was performed using pharmacy claims and infliximab is mostly charged as a medical claim, infliximab use is underestimated in this analysis.
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tests and these CPT codes are also used for other tests. The
annual observed rate of tuberculosis skin or quantiferon tests,
recommended for screening in patients starting with biological
treatment was 0.8%, and of hepatitis B screening 0.8%, and
annual rates of influenza and pneumococcal vaccinations were
1.8% and 0.5%, respectively. However, many of those might not
be billed for independently.
Charges
Annual U.S. medical claim charges for patients with IBD
were in total $4.6 billion, of which 86% ($3.9 billion) were
directly related to IBD care. The medical claim with the highest
share in these charges was infliximab (35%), followed by
colonoscopy with biopsies (4.6%) and intravenous infusion of
chemotherapy/biologics (3.5%). Furthermore, in total, 22% of the
IBD-related medical claim charges were related to endoscopies
and surgeries (including pathology and anesthesia charges), 13%
to physician consultation services, and 9% were for laboratory
tests (Fig. 1A). Patients with a diagnosis code for CD had, on
average, higher annual charges and more claims (mean annual
charge of $5004 with 6 claims on average) compared with pa-
tients with UC (mean annual charge of $2381, with 3 claims on
average). Annual IBD-related pharmacy claims were estimated to
account for a total of $2.9 billion annually. In total, 54% of those
were for aminosalicylates (of which 32% for patients with CD)
and 21% for biologics (Fig. 1B).
Guidelines-derived Care Analysis
We identified 7 guidelines/medical position statements
published between 2003 and 2010 with recommendations relevant
for IBD care; 4 by the American Gastroenterological Association
(AGA)9–12 (all accompanied by technical reviews13–16) and 3 by the
American College of Gastroenterology (ACG).17–19 Four focused
on IBD management,10,12,17,18 2 on colorectal cancer screening,9,19
and 1 on osteoporosis management in gastrointestinal diseases.11
None of the guidelines offered detailed recommendations on the
TABLE 3. Observed Average Annual Rate for Hospital
Visits, Endoscopies, Surgeries, Laboratory
Investigations, and Imaging
IBD, % CD, % UC, %
ER visit 10.7 15.1 4.5
Outpatient visit 93.8 97.4 74.2
Hospitalization 6.5 7.6 4.3
Endoscopy total 42.0 34.1 44.2
Upper GI endoscopy 5.8 6.2 4.7
Colonoscopy 31.3 25.0 33.9
IBD-related surgery total 2.8 3.3 1.6
Resection colon/ileocecal 1.1 1.2 0.8
Fistula/abscess surgery 0.6 0.9 0.1
CBC 32.5 39.5 18.6
CRP 8.8 11.2 4.1
ESR 9.7 12.0 4.8
Liver enzymes 20.4 24.9 11.4
Fecal calprotectin 0.1 0.2 0.1
Fecal lactoferrin 0.1 0.1 0.1
Fecal leukocytes 0.3 0.3 0.3
Influenza vaccinationa 1.8 1.9 1.3
Pneumococcal vaccinationa 0.5 0.5 0.4
Hepatitis B vaccinationa 0.1 0.2 0.1
TB screena 0.8 1.1 0.4
Hepatitis B screeninga 0.8 1.0 0.4
US/MRI/CT abdomen/pelvis 18.1 22.6 11.3
DXA scan 0.6 0.8 0.3
aMight not be billed for independently.
CD, Crohn’s disease; CBC, complete blood count; CRP, C-reactive protein; CT, com-
puted tomography; DXA, dual-energy x-ray absorptiometry; ER, emergency room; ESR,
erythrocyte sedimentation rate, GI, gastrointestinal tract; MRI, magnetic resonance imag-
ing; TB, tuberculosis; UC, ulcerative colitis, US: ultrasound.
FIGURE 1. Origin of charges in medical claims data set (A) and phar-
macy claims data set (B). *Includes anesthesia and pathology. **The
majority of infliximab and natalizumab charges is charged as a medi-
cal claim and is therefore not included in this graph.
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annual frequency of clinic visits, laboratory visits, and endoscop-
ies, with the exception of colorectal screening protocols. Ex-
tracted care recommendations from all guidelines are
summarized in Table, Supplemental Digital Content 6, http://
links.lww.com/IBD/A527.
An overview of expected rates of medication and medical
resource utilization according to guidelines versus the observed
rates is provided in Tables 4 and 5, respectively. Summarized,
we found that although aminosalicylate treatment is not recom-
mended in patients with CD, 42.1% of patients with CD were
prescribed aminosalicylates during the 2-year study period,
which alone accounts for at least 17% of total pharmacy
charges. Metronidazole and ciprofloxacin, indicated for treat-
ment of pouchitis in UC, active fistulizing disease in CD, and
to treat infectious complications, were prescribed to 23% of
patients. However, the claims data did not allow a more
detailed analysis on indications for antibiotic use.
Corticosteroid-sparing medication was used sparsely in
conjunction with corticosteroid therapy (15% thiopurines and
2.7% methotrexate), whereas long-term corticosteroid use was
observed in 9% of patients. Although 9% of patients used cortico-
steroids for more than 105 days consecutively, only 1% underwent
a dual-energy x-ray absorptiometry scan. Furthermore, we found
a low use of surrogate biomarkers for assessment of inflammation,
such as C-reactive protein and/or fecal calprotectin (8.8% and
0.13%, respectively).
DISCUSSION
In this study, we report on U.S. health care utilization in
patients with IBD and found unexpected discrepancies with U.S.
guidelines. This was demonstrated by a disproportionate rate of
aminosalicylate use in CD, common corticosteroid use (including
long-term), and a low rate of corticosteroid-sparing drugs. In
addition, we found only infrequent usage of surrogate biomarkers,
such as C-reactive protein and/or fecal calprotectin.
IBD-related health expenditures are among the highest in
the U.S. health care system.20 A 2012 study based on patient-
reported expenditures from 556 patients with IBD estimated
TABLE 4. Expected Medication Use According to Guidelines Compared with Observed Values
Medication Guidelines Expected Observed







Only recommended for pouchitis or fistula Unknown 23.5%
Budesonide Recommended for UC not for CD No budesonide in UC 3.7% budesonide in UC
Corticosteroids For induction of remission, no long-term use No long-term use 9% long-term use
Immunomodulators/
biologics
Recommended for corticosteroid sparing 46.3% used
corticosteroids
15% of corticosteroid users used concomitant
thiopurines, 2.7% methotrexate. In total 11.0%
biologics use
TABLE 5. Expected Rates of Tests and Procedure in the Data Set According to Guidelines, Compared with the
Observed Values
Procedures Guidelines Expected Observed
Colonoscopy 1· per 1–3 years, 8 years after
diagnosis
Patients with UC .8 yr after diagnosis:
33.3% annual colonoscopy





calprotectin, ESR, orosomucoid, or
CRP
Annual rates: calprotectin: 0.1%; lactoferrin: 0.1%;
fecal leukocytes: 0.3%; CRP: 8.8%; ESR: 9.7%






1· per 1–2 weeks initially, then 1· per
3 months
Patients on immunomodulators per
quarter: 8.7% thiopurines, 1.1%
methotrexate





Patients on immunomodulators per
quarter: 8.7% thiopurines, 1.1%
methotrexate
3.4% 2-mo rate (20.4% annual rate)
CRP, C-reactive protein; DXA, dual-energy x-ray absorptiometry; ESR, erythrocyte sedimentation rate; UC, ulcerative colitis.
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annual IBD-related costs in the United States to be $2.9 billion,20
whereas another claims analysis of 19,420 patients with IBD
estimated annual disease-attributable direct costs to be $6.3 bil-
lion.21 Although we were not able to access actual costs in our
study, we were able to assess the relative contribution of the
different facets of IBD treatment to total IBD-related charges.
We identified biologics to be a major cost component in IBD care,
although their use was restricted to only 11% of patients with IBD
in the observation period. Aminosalicylates accounted for 54% of
pharmacy claim charges, while 32% of the prescriptions were
prescribed for patients with CD, which is not supported by current
guidelines.
Medical insurance claims databases are increasingly used in
health outcomes research, and these data present both opportuni-
ties and limitations.22 A major advantage is that claims are anon-
ymous, plentiful, and available in electronic format. Limitations
include the focus of claims on reimbursement, which is not de-
signed for research purposes; no health outcomes or treatment
goals are available, diagnoses cannot be formally confirmed,
and medical utilization without insurance coverage, such as influ-
enza vaccinations at the workplace, is not captured. Also, because
only claims processed through medical clearinghouses could be
captured in our data set, we were likely not able to capture all U.S.
patients with IBD, a fraction of claims for the identified patients
might not have been included, and no reimbursement rates were
available.
An insurance claims analysis including 19,420 patients with
IBD by Kappelman et al5 found much higher utilization rates because
of more stringent inclusion criteria, thereby excluding patients with
a mild disease phenotype, patients whom our study aimed to include.
In contrast, utilization rates reported in a Northern California study
analyzing 8787 patients with IBD were very similar to our observa-
tions, except for the number of outpatient visits23 (Table, Supplemen-
tal Digital Content 7, http://links.lww.com/IBD/A528). This study
also reported a decline in prolonged steroid exposure from 14% in
1998–1999 to 9% in 2004–2005 annually in CD, and interestingly,
an increase in UC from 11% to 14%. Infliximab use increased from
1% to 5% in CD and from ,0.1% to 0.4% in UC.23 Our results are
in line with these findings and confirm that similar patterns are
observed on a national level.
The observed discrepancies between guidelines and
observed care could be explained in different ways. The New
England Health Institute identified 4 major barriers to guideline
adherence.24
1. The current payment system is problematic, because we
pay for volume of procedures rather than for outcomes;
2. A lack of information technology systems is a barrier
because physicians often have insufficient access to guide-
lines at the point of care and because information technology
does not yet adequately support clinical decision making;
3. The culture, beliefs, and habits of physicians could be bar-
riers because many doctors receive little or no comparative
feedback on their performance; and
4. The current process of development of guidelines presents
an obstacle to adherence. In particular, the lack of trans-
parency in guideline development leads to a lack of trust
among physicians, while guidelines themselves often lack
sufficient flexibility and relevance to clinical practice; many
guidelines do not reflect the complexity and context in
which real-world clinical decisions must be made.24
In summary, in our claims data set of 964,633 patients with
IBD, unprecedented in size, we found relevant discrepancies
between daily care and guideline recommendations on a national
level. The guidelines themselves, in this case for a prototypic
chronic disease, need to be assessed and updated to enable
development of optimal care pathways that are both clinically and
economically efficacious. Future research will need to show the
effect of improved guidelines on adherence, quality of care, and
cost-effectiveness.
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